Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors

Sidéris, Lucas; Dubé, Pierre; Rinke, Anja

doi:10.1634/theoncologist.2011-0458

Cited by 83 publications

(74 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Eriksson and Oberg found that, in studies of octreotide spanning its introduction up to the late 1990s, approximately half of the patients with GEP-NET achieved stabilization of tumour growth (i.e., no increase or decrease in tumour size), with 10-20% showing tumour regression (Eriksson & Oberg 1999). A more recent review that analysed trials conducted between 1987 and 2011 revealed that stable disease in patients with poorly differentiated, functioning or non-functioning GEP-NET was achieved in up to 86% treated with octreotide sc and up to 88% in those receiving octreotide LAR (Sideris et al 2012). Partial tumour response (i.e., a predefined reduction in overall tumour load) reached 31 and 11% for octreotide sc and octreotide LAR, respectively, broadly in agreement with the earlier findings by Eriksson and Oberg (Eriksson & Oberg 1999).…”

Section: Antitumour Effectmentioning

confidence: 99%

Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future

Öberg¹,

Lamberts²

2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

Acromegaly is a hormonal disorder that arises when the pituitary gland secretes excess growth hormone (GH), which in turn stimulates a concomitant increase in serum insulin-like growth factor 1 (IGF-1) levels. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) constitute a heterogeneous group of tumours that can secrete serotonin and a variety of peptide hormones that may cause characteristic symptoms known as carcinoid syndrome or other symptoms and hormonal hypersecretion syndromes depending on the tumour's site of origin. Current medical therapy for the treatment of acromegaly and GEP-NET involves the administration of somatostatin analogues that effectively suppress excess hormone secretion. After its discovery in 1979, octreotide became the first synthetic biologically stable somatostatin analogue with a short-acting formulation of octreotide introduced into clinical practice in the late 1980s. Lanreotide, another somatostatin analogue, became available in the mid-1990s initially as a prolonged-release formulation administered every 10 or 14 days. Long-acting release formulations of both octreotide (Sandostatin LAR and Novartis) and lanreotide (Somatuline Autogel, Ipsen), based on microparticle and nanoparticle drug-delivery technologies, respectively, were later developed, which allowed for once-monthly administration and improved convenience. First-generation somatostatin analogues remain one of the cornerstones of medical therapy in the management of pituitary and GEP-NET hormone hypersecretion, with octreotide having the longest established efficacy and safety profile of the somatostatin analogue class. More recently, pasireotide (Signifor), a next-generation multireceptor-targeted somatostatin analogue, has emerged as an alternative therapeutic option for the treatment of acromegaly. This review summarizes the development and clinical success of somatostatin analogues.

show abstract

Section: Antitumour Effectmentioning

confidence: 99%

Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future

Öberg¹,

Lamberts²

2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…Octreotide and lanreotide are somatostatin analogs proved to be useful in alleviation of of flushing and diarrhea which are associated with NETs secretion (55,56). The antitumor effect of somatostatin analogs has been established in many clinical trials (57)(58)(59).…”

Section: Neuropeptides and Cancermentioning

confidence: 99%

Molecular challenges of neuroendocrine tumors (Review)

Patel

Galoian

2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. Neuroendocrine tumors (NETs) are a very heterogeneous group that are thought to originate from the cells of the endocrine and nervous systems. These tumors develop in a number of organs, predominantly in the gastrointestinal and pulmonary systems. Clinical detection and diagnosis are reliable at the late stages when metastatic spread has occurred. However, traditional conventional therapies such as radiation and chemotherapy are not effective. In the majority of cases even surgical resection at that stage is unlikely to produce promising reusults. NETs present a serious clinical challenge, as the survival rates remain low, and as these rare tumors are very difficult to study, novel approaches and therapies are required. This review will highlight the important points of accumulated knowledge covering the molecular aspects of the role of neuroendocrine cells, hormonal peptides, the reasons for ectopic hormone production in NET, neuropeptides and epigenetic regulation as well as the other challenging questions that require further understanding.

show abstract

“…Again, both these analogs have been reported to have an antiproliferative effect in vitro [52,53] . Data from uncontrolled prospective and retrospective clinical series [54][55][56] showed tumor shrinkage and disappearance in response to either short-acting SSAs alone or when combined with interferon-α. Further trials have reported tumor stabilization in up to 50% of patients, but without complete regression.…”

Section: Management Of Type-i Gastric Carcinoid -A Clinical Challengementioning

confidence: 99%